Examining dyslipidaemia, metabolic syndrome and liver enzyme levels in patients with prediabetes and type 2 diabetes in population from Hoveyzeh cohort study: A case–control study in Iran

Dinarvand, Negar; Cheraghian, Bahman; Rahimi, Zahra; Bavarsad, Samaneh Salehipour; Bavarsad, Amirhooshang; Mohammadtaghvaei, Narges

doi:10.1002/edm2.401

Cited by 4 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metabolic syndrome (MS) is a cluster of cardiometabolic risk factors, such as abdominal obesity, high blood pressure, hyperglycemia, and dyslipidemia ( 1 ), that increase the risk of developing cardiovascular and other chronic age-related diseases ( 2 , 3 ).…”

Section: Introductionmentioning

confidence: 99%

Sleep behavior and daily activity levels in people with metabolic syndrome: effect of 1 year of metformin treatment

Bruno,

Mulè,

Galasso

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

Impaired sleep and low daily activity levels increase the risk of developing metabolic syndrome (MS). Metformin (MET), an insulin sensitizer drug, is effective in regressing MS and has been recently studied as an adjuvant agent for managing sleep disorders. The present study aimed to assess whether 1,700 mg/day of MET treatment modifies sleep and daily activity levels in people with MS evaluated by Rest-Activity circadian Rhythm (RAR), which is the expression of 24 h of spontaneous activity parameters. A total of 133 subjects with MS, randomized into the MET (n = 65) or placebo (PLA, n = 68) group, underwent a clinical/anthropometric examination and carried out a continuous 7-day actigraphic monitoring to investigate sleep and RAR parameters at baseline and after 1 year of intervention. After 1 year of intervention, 105 subjects were analyzed. The MET group showed greater anthropometric and metabolic improvements compared with placebo, with a significant reduction in weight (p = 0.01), body mass index (p = 0.01), waist circumference (p = 0.03), and glucose (p < 0.001). With regard to sleep parameters, the MET group showed a significant increase in actual sleep time (p = 0.01) and sleep efficiency (p = 0.04) compared with placebo. There were no significant changes reported in the RAR parameters. Our study suggests that MET might be used as an adjuvant treatment for sleep disorders in people with MS.

show abstract